|
|
| Line 1: |
Line 1: |
| | {{Fudan-CHINA}} | | {{Fudan-CHINA}} |
| | <html> | | <html> |
| − | <head>
| |
| | | | |
| − | <style type="text/css">
| |
| − | .step{font-family:Algerian;
| |
| − | font-size: 11em;
| |
| − | color: white;
| |
| − | left: 800px;
| |
| − | position: absolute;
| |
| − | top: 330px;
| |
| − |
| |
| − | }
| |
| − | .abstract{
| |
| − | font-family:Baskerville, "Palatino Linotype", Palatino, "Century Schoolbook L", "Times New Roman", "serif";
| |
| − | color: white;
| |
| − | font-size: 1.8em;
| |
| − | position: absolute;
| |
| − | width: 1400px;
| |
| − | left: 250px;
| |
| − | top: 580px;
| |
| − | line-height:25px;
| |
| − | text-align: justify;/*两端对齐*/
| |
| − | font-weight: 600;/*粗度*/
| |
| − | }
| |
| − | .fullname{
| |
| − | font-family:Cambria, "Hoefler Text", "Liberation Serif", Times, "Times New Roman", "serif";
| |
| − | color: white;
| |
| − | font-size: 2em;
| |
| − | position: absolute;
| |
| − | left:800px;
| |
| − | top:430px;
| |
| − | display: block;
| |
| − |
| |
| − | }
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | html,body {
| |
| − | margin: 0;
| |
| − | }
| |
| − |
| |
| − | * {
| |
| − | -webkit-box-sizing: border-box;
| |
| − | -moz-box-sizing: border-box;
| |
| − | box-sizing: border-box;
| |
| − | }
| |
| − | img {
| |
| − | border: 0;
| |
| − | }
| |
| − |
| |
| − | html, body, div, ul, li, img {
| |
| − | margin: 0;
| |
| − | padding: 0;
| |
| − | }
| |
| − |
| |
| − | li {
| |
| − | list-style: none;
| |
| − | }
| |
| − |
| |
| − | /* 必要布局样式css */
| |
| − | .banner-content{
| |
| − | position: absolute;
| |
| − | top:-12px;
| |
| − | left: -20px;
| |
| − | }
| |
| − | .banner-slide-circle {
| |
| − | position: absolute;
| |
| − | bottom: 3%;
| |
| − | z-index: 1002;
| |
| − | left: 50%;
| |
| − |
| |
| − | }
| |
| − |
| |
| − | .banner-slide-circle ul li {
| |
| − | width: 11px;
| |
| − | height: 11px;
| |
| − | background: #bdccd4;
| |
| − | border-radius: 50%;
| |
| − | cursor: pointer;
| |
| − | float: left;
| |
| − | margin: 0 8px;
| |
| − | }
| |
| − |
| |
| − | .banner-slide-circle ul .on {
| |
| − | background: #45aaf2;
| |
| − | }
| |
| − |
| |
| − | .banner-slide-image ul li img {
| |
| − | width:100%;
| |
| − | height:auto;
| |
| − | }
| |
| − |
| |
| − | </style>
| |
| − | </head>
| |
| − |
| |
| − |
| |
| − |
| |
| − | <body style="margin:0; padding:0;">
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | <div class="banner-content">
| |
| − | <div class="banner-slide">
| |
| − | <div class="banner-slide-circle hd">
| |
| − | <ul>
| |
| − | <li class="on"></li>
| |
| − | <li></li>
| |
| − | <li></li>
| |
| − |
| |
| − | </ul>
| |
| − | </div>
| |
| − |
| |
| − | <div class="banner-slide-image bd">
| |
| − | <ul>
| |
| − | <li>
| |
| − | <img src="https://static.igem.org/mediawiki/2018/8/8f/T--Fudan-CHINA--bgpicture2.jpeg" alt="">
| |
| − | </li>
| |
| − | <li>
| |
| − | <img src="https://static.igem.org/mediawiki/2018/8/8d/T--Fudan-CHINA--bgpicture3.jpeg" alt="">
| |
| − | </li>
| |
| − | <li>
| |
| − | <img src="https://static.igem.org/mediawiki/2018/9/92/T--Fudan-CHINA--bgpicture1.jpeg" alt="">
| |
| − | </li>
| |
| − |
| |
| − | </ul>
| |
| − | </div>
| |
| − | </div>
| |
| − |
| |
| − |
| |
| − |
| |
| − | </div>
| |
| − |
| |
| − | <script type="text/javascript">
| |
| − |
| |
| − | jQuery(".banner-slide").slide({mainCell:".bd ul",autoPlay:true,effect:"fold",delayTime:1000,mouseOverStop:false});
| |
| − |
| |
| − | </script>
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − | <img src="https://static.igem.org/mediawiki/2018/1/1d/T--Fudan-CHINA--step_white.png" width="250" height="250" style="position:absolute; left:500px; top:250px;" alt="badge">
| |
| − |
| |
| − | <div class="step">S T E P</div>
| |
| − |
| |
| − | <div class="abstract">
| |
| − | Cell therapy has shown great potential in cancer treatment these years, while the existing CAR-T cell therapy can only target on cell surface antigens. However, there are also many tumour markers free in the blood, also being important targets marking the location of tumour. <br><br>
| |
| − |
| |
| − | Here we manage to construct a brand new transducer system, named STEP, to recognise small, soluble tumour markers (e.g. VEGF, AFP, TSGF). For that purpose, we adapt and optimise a newly developed system to transduce the input (free ligands) into release of a transcription factor and expression of desired drugs. To increase the recognition ability, we use Rosetta to redesign the interface between ligand and receptor in order to enhance the binding affinity.<br><br>
| |
| − |
| |
| − | Our STEP system can be applied for detecting tumour markers in blood and secrete drug in real time to appropriate tissues, providing a new yet practical approach for cell therapy and cancer treatment.<br><br>
| |
| − | </div>
| |
| − | <div class="fullname">
| |
| − | Synthetic Transducer Engineering Platform
| |
| − | </div>
| |
| − |
| |
| − |
| |
| − | </body>
| |
| | | | |
| | </html> | | </html> |
